Aurinia Pharmaceuticals Inc.
AUPH
$8.18
$0.080.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 33.97% | 38.72% | 29.35% | 30.37% | 30.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.97% | 38.72% | 29.35% | 30.37% | 30.95% |
| Cost of Revenue | -23.13% | -14.14% | 18.77% | 23.67% | 25.94% |
| Gross Profit | 66.57% | 70.29% | 34.50% | 33.98% | 34.00% |
| SG&A Expenses | -11.80% | -3.83% | -3.24% | -4.32% | -0.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -37.35% | 216.34% | 124.12% | 27.41% | 262.77% |
| Total Operating Expenses | -14.81% | -3.84% | 4.39% | 1.68% | 6.44% |
| Operating Income | 114.59% | 78.88% | 43.56% | 39.15% | 23.04% |
| Income Before Tax | 109.61% | 73.58% | 32.38% | 34.70% | 27.16% |
| Income Tax Expenses | 207.80% | 154.59% | 40.49% | -62.11% | -69.86% |
| Earnings from Continuing Operations | 107.37% | 70.78% | 30.78% | 35.34% | 27.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 107.37% | 70.78% | 30.78% | 35.34% | 27.88% |
| EBIT | 114.59% | 78.88% | 43.56% | 39.15% | 23.04% |
| EBITDA | 143.11% | 100.59% | 66.31% | 53.20% | 31.83% |
| EPS Basic | 107.47% | 70.97% | 31.19% | 35.82% | 28.41% |
| Normalized Basic EPS | 139.53% | 83.82% | 43.55% | 42.16% | 27.70% |
| EPS Diluted | 107.41% | 70.91% | 31.19% | 35.82% | 28.82% |
| Normalized Diluted EPS | 138.38% | 83.46% | 43.55% | 42.16% | 27.70% |
| Average Basic Shares Outstanding | 0.24% | 0.55% | 0.69% | 0.78% | 0.71% |
| Average Diluted Shares Outstanding | 1.80% | 1.14% | 0.83% | 0.78% | 0.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |